Biogen's Nicole Murphy on Drug Delivery Innovation and the Acquisition of Alcyone Therapeutics

Nicole Murphy is Executive Vice President, Head of Pharmaceutical Operations and Technology of Biogen and joined the Executive Committee in 2022. Ms. Murphy joined Biogen in 2015 and has held senior executive positions, including most recently as Senior Vice President, Head of Global Manufacturing & Technical Operations (GMTO).  In 2017, Ms. Murphy played a critical role during the successful spin-off of Biogen’s hemophilia franchise, as the Vice President and Head of Technical Operations of Bioverativ and prior to the spin-off was the General Manager and Head of Cambridge Site Operations at Biogen. Ms. Murphy has extensive experience in leading Supply Chain, Quality, Process Development, Manufacturing and Engineering functions. Prior to joining Biogen Ms. Murphy spent over 15 years at Amgen.Ms. Murphy holds an MS in Chemical Engineering, an MBA from Rensselaer Polytechnic Institute, and a BS in Engineering from the University of Massachusetts at Amherst. Ms. Murphy serves on a variety of industry councils and committees.